Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. “
Separately, Cantor Fitzgerald restated a “hold” rating and set a $3.00 target price on shares of Sunesis Pharmaceuticals in a research note on Thursday, July 27th.
Sunesis Pharmaceuticals (NASDAQ:SNSS) opened at 2.47 on Wednesday. The firm has a 50-day moving average price of $2.73 and a 200-day moving average price of $3.50. The company’s market cap is $58.08 million. Sunesis Pharmaceuticals has a 12-month low of $2.47 and a 12-month high of $6.30.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.76) by $0.35. During the same period in the previous year, the company earned ($0.12) EPS. On average, analysts forecast that Sunesis Pharmaceuticals will post ($1.61) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) Stock Rating Upgraded by Zacks Investment Research” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://stocknewstimes.com/2017/08/04/sunesis-pharmaceuticals-inc-nasdaqsnss-stock-rating-upgraded-by-zacks-investment-research.html.
Hedge funds have recently bought and sold shares of the stock. TFS Capital LLC purchased a new stake in Sunesis Pharmaceuticals during the first quarter valued at $158,000. Renaissance Technologies LLC increased its stake in Sunesis Pharmaceuticals by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 110,581 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 16,000 shares during the last quarter. Finally, Neuberger Berman Group LLC increased its stake in Sunesis Pharmaceuticals by 16.6% in the first quarter. Neuberger Berman Group LLC now owns 140,555 shares of the biopharmaceutical company’s stock valued at $576,000 after buying an additional 20,000 shares during the last quarter. Institutional investors and hedge funds own 55.15% of the company’s stock.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
